A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients

Running, not enrolling · Phase 4

Conditions studied: Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection

In brief

This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.

Key facts

Study ID

NCT04508907

Run by

Mayo Clinic

People needed

200

Starts

2020-09-10

Expected to finish

2026-11-01

Last updated by the study team

2025-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Listed kidney, heart, lung and/or pancreas patients who are negative for chronic hepatitis C infection
• Willing to accept and consent for accepting hepatitis C positive graft

You may not qualify if…

• Existing chronic liver disease (liver cirrhosis)
• Concomitant infection with HIV or Chronic hepatitis B
• Patient or any member of patient family or care giver team who does not understand or accept the risk of an acquired HCV infection
• Pregnancy (Pregnant patients do not undergo solid organ transplants)

Where it is running

• Mayo Clinic in Arizona — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.